Forecasting PARP Inhibitor Resistance in Breast Cancer Patients

Despite a relatively small, though increasing, level of focus in oncology, radiation-induced heart damage in breast cancer is a relevant clinical problem that needs more attention.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

The test led to a modification in treatment plan for 48.1% of those with stage I to III HER2-positive breast cancer, 73.5% of which were reductions.

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Findings from the COMET trial support the potential safety and acceptability of active monitoring among patients with ductal carcinoma in situ.

The assistance of AI-based computer-aided detection for mammogram screenings did not impact recall rates in a radiologist’s standard single reading.